Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Sept. 25-28, 2019
Espace Grand Arche de la Defense
Paris, France

Conference Cochairs
Christoph Huber, Association for Cancer Immunotherapy, Mainz, Germany
Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France
Ellen Puré, University of Pennsylvania, Philadelphia, Pennsylvania
Giorgio Trinchieri, National Cancer Institute, Frederick, Maryland

Scientific Planning Committee
Sandra Demaria, Weill Cornell Medical College, New York, New York
Wolf Hervé Fridman, Centre de Recherche des Cordeliers, Paris, France
Nir Hacohen, Massachusetts General Hospital and Broad Institute, Cambridge, Massachusetts
Sebastian Kreiter, Johannes Gutenberg University, Mainz, Germany
Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals, Leiden, The Netherlands
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York
Catherine Sautès-Fridman, Université Paris-Descartes, Paris, France
Robert D. Schreiber, Washington University School of Medicine, St. Louis, Missouri
Özlem Türeci, BioNTech AG, Mainz, Germany
E. John Wherry, Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Laurence Zitvogel, Institut Gustave Roussy, Paris, France

The Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to present the Fifth International Cancer lmmunotherapy Conference.

The 2019 meeting will be held at the Espace Grande Arche in Paris, France from September 25-28, 2019. The program will focus on "Translating Science into Survival," and feature talks from more than 50 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy, including: regulating T cells and their response to cancer, tumor microenvironment, genetically engineered T cells, maintenance of immune balance, novel vaccine platforms and combinations, mutational analysis and predicting response to immunotherapy, convergence of technology and cancer immunotherapy, microbiome, and metabolism. 

This meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.